MannKind Corp., advised by Cooley LLP, announced Monday it will acquire ScPharmaceuticals Inc., represented by Latham & Watkins LLP, in a $360 million deal that signals a bold leap into the cardiometabolic space.
Under the agreement, MannKind will purchase all outstanding shares of ScPharmaceuticals’ common stock at $6.35 per share in cash, a move that cements its ambition to diversify beyond its orphan lung portfolio.
Furoscix: A Key Driver Behind the Acquisition
ScPharmaceuticals is best known for its FDA-approved on-body infuser, Furoscix, designed to treat fluid overload in adults with chronic heart failure and kidney disease. The device offers an innovative, patient-friendly alternative to intravenous diuretics, making it a standout product in a field with growing demand.
“This transaction with MannKind represents an exciting next chapter for ScPharmaceuticals and the Furoscix brand,” said CEO John Tucker. “By combining our innovative products with MannKind’s proven commercial capabilities, we can accelerate patient access to essential therapies and create meaningful value for patients, providers, and shareholders.”
